

Accepted Manuscript

Rituximab as first line adjuvant in pemphigus: retrospective analysis of the long-term outcomes in a single center

Keshavamurthy Vinay, MD, DNB, Simone Cazzaniga, MD, Kyle T. Amber, MD, Laurence Feldmeyer, MD, PhD, Luigi Naldi, MD, Luca Borradori, MD



PII: S0190-9622(17)32689-0

DOI: [10.1016/j.jaad.2017.11.024](https://doi.org/10.1016/j.jaad.2017.11.024)

Reference: YMJD 12127

To appear in: *Journal of the American Academy of Dermatology*

Received Date: 12 August 2017

Revised Date: 31 October 2017

Accepted Date: 5 November 2017

Please cite this article as: Vinay K, Cazzaniga S, Amber KT, Feldmeyer L, Naldi L, Borradori L, Rituximab as first line adjuvant in pemphigus: retrospective analysis of the long-term outcomes in a single center, *Journal of the American Academy of Dermatology* (2017), doi: 10.1016/j.jaad.2017.11.024.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Rituximab as first line adjuvant in pemphigus: retrospective analysis of the long-term outcomes in a single center

Running head: First line rituximab in pemphigus

Keshavamurthy Vinay MD, DNB,^{1,2} Simone Cazzaniga MD,^{1,3} Kyle T. Amber MD,⁴ Laurence Feldmeyer MD, PhD,¹ Luigi Naldi MD,^{1,3,4} Luca Borradori MD¹

¹ Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

² Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India-160012

³ Centro Studi GISED, Bergamo, Italy

⁴ Department of Dermatology, San Bortolo Hospital, Vicenza, Italy

⁵ Department of Dermatology, University of California Irvine Health, Irvine, CA, USA.

Correspondence and reprint request:

Dr. Keshavamurthy Vinay

Department of Dermatology, Inselspital, Bern University Hospital, Switzerland

Email: vinay.keshavmurthy@gmail.com

Word count: 594

Table count: 2

No of references: 5

Funding source: The study was supported by the International society of Dermatology

Mentorship grant provided to K.V. L.B. is supported by Swiss National Science

Foundation (grant number 310030E-171664; FOR 2497_PEGASUS_TP7)

Conflict of interest: None

IRB status: Approved

Keywords: Complete remission; First line; Pemphigus; Relapse; Rituximab

Rituximab has been widely used for treatment-refractory pemphigus, but the experience as first line steroid-sparing agent is limited.^{1,2} In this retrospective study we assessed if early use of rituximab in the disease course would improve the long-term clinical outcome.

All pemphigus vulgaris and pemphigus foliaceus patients evaluated between January 2008 and December 2016 at our institute and systematically treated with rituximab were included. Group A encompassed patients who received rituximab as a first line steroid-sparing adjuvant within 6 months of diagnosis without any conventional immunosuppressants. Group B consisted of patients with disease activity who received rituximab after failing corticosteroids/conventional immunosuppressants or for relapse after them. Patients in both groups were treated with two infusions of 1000 mg rituximab, two weeks apart. Patients who relapsed or failed to achieve clinical remission (CR)³ in 6 months were re-treated with a single infusion (1000mg) of rituximab.. In addition, patients in both groups received oral corticosteroids with a starting dose of prednisolone between 0.5 to 1 mg/kg with invariably a quick taper and withdrawal of the corticosteroids within 6 months depending on the severity of the disease and clinical judgement.

The primary aim was to compare the efficacy between the two groups in terms of achieving CR off treatment. The secondary outcomes were CR on minimal therapy, relapse rate, requirement of repeat infusions and rituximab-related adverse events.³

The baseline characteristics of the two groups are summarized in **Table 1**. In group A, 7/9 (estimated cumulative rate 87.5%) patients and 12/20 (66.2%) patients in group B achieved CR off therapy (p=0.01). After accounting for the effect of disease duration, the hazard ratio between the two groups was still statistically significant (HR: 6.10, 95% CI: 1.52 - 24.44, p=0.01).

When both minimal therapy and off therapy was considered, CR was achieved by 8/9 (estimated cumulative rate 100%) patients in group A and 19/22 (92.9%) patients in group B without any statistically significant difference (**Table 2**). Relapse was seen in 4/9 (44.4%) and 7/22 (31.8%) patients in group A and B respectively. Five/9 (55.6%) patients in group A and 6/22 (35.5%) patients in group B were administered repeated infusions of rituximab, with three (33.3%) and two (9.1%) patients respectively receiving two or more repeat infusions. No significant difference was found between the two groups regarding the time to first relapse ($p=0.33$).

In our study CR off treatment was more likely to be achieved by patients receiving rituximab earlier in the disease (<6 months) and as first-line steroid sparing adjuvant. Even when accounting for prolonged disease durations, our results were still significant. Given the limits of our sample size, we were unable to account for additional potential cofounders such as disease subtype or the use of different adjuvant therapies. However, previous analyses have failed to show any effect of these cofounders on clinical outcomes.⁴ Thus, it is unlikely they contributed to the difference in our observed responses. Noteworthy, despite the differences in early outcome, there was no difference between the groups in any of the secondary end points. The higher requirement of repeat infusions in group A is skewed by its small sample size and two of the patients requiring re-treatment for failure to achieve CR. A prospective multicentre study encompassing 91 pemphigus patients has shown that first-line use of rituximab in combination with short-term prednisone allows to achieve CR off treatment in a three times greater portion of patients than using prednisone alone and was associated with significantly fewer grade 3 and 4 side effects.⁵ These findings support the use of rituximab with low dose corticosteroids as first-line regimen in pemphigus.

81 **Abbreviation**

82 CR: complete remission

83 HR: hazard ratio

References:

- 1 Ahmed AR, Shetty S. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. *Autoimmun Rev* 2015; **14**:323–31.
- 2 Leventhal JS, Sanchez MR. Is it time to re-evaluate the treatment of pemphigus? *J Drugs Dermatol* 2012; **11**:1200–6.
- 3 Murrell DF, Dick S, Ahmed AR, *et al.* Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. *J Am Acad Dermatol* 2008; **58**:1043–6.
- 4 Amber KT, Hertl M. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. *J Eur Acad Dermatol Venereol* 2015; **29**:777–82.
- 5 Joly P, Maho-Vaillant M, Prost-Squarcioni C, *et al.* First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. *Lancet* 2017; **389**:2031–40.

Table 1. Demographics and clinical characteristics of the included patients

		Group A (N=9)		Group B (N=22)		P**
		N*	%	N*	%	
Sex	M	3	33.3%	8	36.4%	1
	F	6	66.7%	14	63.6%	
Age (years)	Mean, SD	62.5	17.9	54.8	16.7	0.66
Age at diagnosis (years)	Mean, SD	62.2	18.0	51.3	16.4	0.24
Disease duration prior to rituximab (weeks)	Mean, SD	15.1	7.1	180.8	142.5	<0.001
Type of pemphigus	PV	4	44.4%	15	71.4%	0.22
	PF	5	55.6%	6	28.6%	
Previous treatments	Azathioprine	-	-	14	66.7%	-
	MMF	-	-	5	23.8%	
	Cyclophosphamide	-	-	1	4.8%	
	Methotrexate	-	-	1	4.8%	
	Dapsone	-	-	2	9.5%	
	Others	-	-	1	4.8%	
Number of previous treatments	0	-	-	1	4.8%	-
	1	-	-	16	76.2%	
	2 or more	-	-	4	19.0%	
Baseline cutaneous severity (ABSIS)	Mean, SD	9.7	10.7	7.7	7.5	1
Baseline mucosal severity*	None	5	55.6%	6	28.6%	0.23
	Mild (<5% area involved)	1	11.1%	10	47.6%	
	Moderate (5%-30% area involved)	2	22.2%	3	14.3%	
	Severe (>30% area involved)	1	11.1%	2	9.5%	
Dsg 1	Negative	3	33.3%	6	27.3%	0.69
	0 - 99	2	22.2%	9	40.9%	
	100+	4	44.4%	7	31.8%	
Dsg 3	Negative	4	44.4%	6	27.3%	0.55
	0 - 99	3	33.3%	7	31.8%	
	100+	2	22.2%	9	40.9%	

PV: pemphigus vulgaris; PF: pemphigus foliaceus; SD: standard deviation; Dsg: Desmoglein ELISA values in U/ml ; MMF: mycophenolate mofetil;

* Numbers may not add up to the total due to missing data

** Fisher's exact test or Mann-Whitney U test for categorical and continuous variables, respectively

Table 2. Cumulative rates and hazard ratios of patients achieving complete remission (CR) and of patients remaining in CR, overall and by kind of rituximab treatment

	Group A	Group B	P*	HR, A vs. B (95% CI)	P**
CR off therapy, % (95% CI)	87.5% (64.6 - 100)	66.2% (43.7 - 88.7)	0.01	6.10 (1.52 - 24.44)	0.01
N patients	9	20			
N events	7	12			
Max time, weeks	128.1	414.9			
Median time to achieve CR, weeks (95% CI)	39.7 (30.4 - 49.0)	72.3 (0 - 184.7)			
CR on minimal therapy and off therapy, % (95% CI)	100% (NC)	92.9% (80.6 - 100)	0.46	1.03 (0.35 - 3.07)	0.96
N patients	9	22			
N events	8	19			
Max time, weeks	119.7	213.9			
Median time to achieve CR, weeks (95% CI)	30.9 (13.8 - 47.9)	29.7 (26.5 - 32.9)			
Patients remaining in CR, % (95% CI)	33.3% (0 - 70.9)	61.1% (38.6 - 83.6)	0.33	1.19 (0.28 - 5.04)	0.82
N patients	8	19			
N events	4	7			
Max time, weeks	127.4	396.0			
Median survival time, weeks (95% CI)	51.9 (19.4 - 84.3)	NC			

CI: confidence interval, HR: hazard ratio, NC: not computable

112 * Log-rank test

113 ** P-value from Cox regression models including disease duration prior to rituximab as adjustment
114 variable

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136